Advanced

A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.

Mukherjee, Oindrilla LU ; Singh, Birendra LU ; Bayrak, Burcu LU ; Jonsson, Ann-Beth; Mörgelin, Matthias LU and Riesbeck, Kristian LU (2015) In Human Vaccines & Immunotherapeutics 11(9). p.2223-2227
Abstract
Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in... (More)
Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in meningococcal vaccines. This study thus highlights the applicability of the menigococcal-Moraxella fusion protein NID to be used for specific targeting of vaccine components to the IgD B cell receptor. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Human Vaccines & Immunotherapeutics
volume
11
issue
9
pages
2223 - 2227
publisher
Taylor & Francis
external identifiers
  • pmid:26042357
  • wos:000360493900024
  • scopus:84954563915
ISSN
2164-5515
DOI
10.1080/21645515.2015.1034917
language
English
LU publication?
yes
id
10e18ea2-7637-4f32-b23c-dca89228d5d3 (old id 7488240)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26042357?dopt=Abstract
date added to LUP
2015-07-07 11:02:59
date last changed
2017-01-01 03:38:04
@article{10e18ea2-7637-4f32-b23c-dca89228d5d3,
  abstract     = {Moraxella IgD-binding protein (MID) is a well characterized trimeric autotransporter that specifically targets the IgD of B cells. We fused the membrane anchor of the meningococcal autotransporter NhhA with the IgD-binding region of MID (aa 962-1200) to create a chimeric protein designated as NID. The aim was to use this specific targeting to provide a better vaccine candidate against meningococci, in particular serogroup B by enhancing the immunogenicity of NhhA. NID was thereafter recombinantly expressed in E. coli. The NID-expressing E. coli bound to peripheral B lymphocytes that resulted in cellular activation. Furthermore, we also successfully expressed NID on outer membrane vesicles, nanoparticles that are commonly used in meningococcal vaccines. This study thus highlights the applicability of the menigococcal-Moraxella fusion protein NID to be used for specific targeting of vaccine components to the IgD B cell receptor.},
  author       = {Mukherjee, Oindrilla and Singh, Birendra and Bayrak, Burcu and Jonsson, Ann-Beth and Mörgelin, Matthias and Riesbeck, Kristian},
  issn         = {2164-5515},
  language     = {eng},
  number       = {9},
  pages        = {2223--2227},
  publisher    = {Taylor & Francis},
  series       = {Human Vaccines & Immunotherapeutics},
  title        = {A fusion protein derived from Moraxella catarrhalis and Neisseria meningitidis aimed for immune modulation of human B cells.},
  url          = {http://dx.doi.org/10.1080/21645515.2015.1034917},
  volume       = {11},
  year         = {2015},
}